Paratek Pharmaceuticals Inc., a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon tetracycline chemistry, opened its new corporate headquarters in Boston at 75 Park Plaza.

“This move comes at an important time for Paratek, as we have recently initiated a global Phase 3 program for our lead antibiotic compound, omadacycline. With two important products in Phase 3 clinical studies, we are now preparing for the next phase of our growth as a biopharmaceutical company,” said Michael Bigham, chairman and chief executive officer, Paratek. “The company takes pride in its origins as a Boston-based biopharmaceutical company, and we look forward to our continued growth here in Boston.”

The address of the new headquarters is 75 Park Plaza, 4th floor, Boston, MA 02116. Paratek was previously located at 75 Kneeland Street in Boston. In June Paratek opened a second office location in the Philadelphia area.